Anogenital distance as a toxicological or clinical marker for fetal androgen action and risk for reproductive disorders

Camilla Lindgren Schwartz1 · Sofie Christiansen1 · Anne Marie Vinggaard1 · Marta Axelstad1 · Ulla Hass1 · Terje Svingen1

Received: 5 September 2018 / Accepted: 8 November 2018 / Published online: 14 November 2018 © The Author(s) 2018

Abstract
Male reproductive development is intricately dependent on fetal androgen action. Consequently, disrupted androgen action during fetal life can interfere with the development of the reproductive system resulting in adverse effects on reproductive function later in life. One biomarker used to evaluate fetal androgen action is the anogenital distance (AGD), the distance between the anus and the external genitalia. A short male AGD is strongly associated with genital malformations at birth and reproductive disorders in adulthood. AGD is therefore used as an effect readout in rodent toxicity studies aimed at testing compounds for endocrine activity and anti-androgenic properties, and in human epidemiological studies to correlate fetal exposure to endocrine disrupting chemicals to feminization of new-born boys. In this review, we have synthesized current data related to intrauterine exposure to xenobiotics and AGD measurements. We discuss the utility of AGD as a retrospective marker of in utero anti-androgenicity and as a predictive marker for male reproductive disorders, both with respect to human health and rodent toxicity studies. Finally, we highlight four areas that need addressing to fully evaluate AGD as a biomarker in both a regulatory and clinical setting.

Keywords Anogenital distance · Reproduction · Endocrine disruptors · Toxicology · Risks assessment

Introduction

Few things permeate our lives more than our sex and reproductive capacity, influencing not only our physical characteristics, but also behaviour and social perception. Ensuring proper reproductive development and life-long health therefore seems obvious, yet modern living is increasingly putting pressure on the processes of sexual differentiation and reproductive function. Exposure to endocrine disrupting chemicals (EDCs) during fetal life in both males and females has been raised as particularly disconcerting, since this is the period when the sexual organs form and, in many respects, lay the foundation for adult reproductive health (Johansson et al. 2017; Skakkebaek et al. 2016). Much effort has thus been invested in understanding the relationships between fetal exposure to xenobiotics and reproductive disorders, as well as to devise testing strategies to screen chemicals for potential endocrine disrupting effects.

In males, reproductive disorders associated with impaired fetal testis development or function vary in both phenotype and time of manifestation. Often described by the ‘testicular dysgenesis syndrome’ hypothesis (Skakkebaek et al. 2016), these male disorders range from hypospadias and cryptorchidism in infants (Hsieh et al. 2008, 2012; Jain and Singal 2013; Thankamony et al. 2014), to low testosterone levels, impaired semen quality and fertility issues in adult men (Eisenberg et al. 2011, 2012; Mendiola et al. 2011). Because of this complexity, it is difficult to adopt a single biomarker to use in animal toxicity studies aimed at testing chemicals for potential adverse effects on male reproductive health. The anogenital distance (AGD), however, is considered a broad biomarker capable of both retrospectively determine...
early-life androgen disruption and predict late-life reproductive disorders in male offspring (Dean and Sharpe 2013; Thankamony et al. 2016).

The AGD refers to the distance between the anus and the external genitalia, and is approximately twice the length in male compared to female new-borns. This sexual dimorphism is apparent in rodents as well as humans (Salazar-Martinez et al. 2004; Thankamony et al. 2009) and is a consequence of the androgen-driven dimorphic differentiation of the two sexes (Fig. 1). This sexual bifurcation extends to the perineum, where a muscular complex develops in males, but not in females. A short male AGD is, therefore, considered a marker of disrupted androgen action. In rodents, a short male AGD largely predicts the same adverse effect outcomes as in humans. In fact, the idea of investigating AGD in human epidemiological studies came from rodent developmental and reproductive toxicity studies, where AGD had been used for decades as a marker of impaired fetal androgen action and regarded as an adverse outcome (Tables 1, 2).

In this review, we discuss current knowledge concerning AGD measurements, both as a clinical marker in humans and as a morphometric measure of fetal androgen disturbance in rodent toxicity studies. We have collated a growing body of toxicological studies that have reported on AGD measurements to gain a better overview of what evidence support the exclusive androgen-driven masculinization thesis, or to tease out other potential mechanisms that may lead to similar effects on AGD. However, first, to better appreciate why the AGD is a useful marker to assess early-life androgen disruption, we need to broadly outline how the two sexes develop.

Sexual differentiation and the importance of early androgen signaling

From gonadal sex determination to testosterone synthesis

At first, the male and female embryos are morphologically indistinguishable and only differentiate down two distinct trajectories after the appearance of either testes or ovaries. The specification of reproductive sex, or gonadal sex determination, is genetically controlled by the Y-linked sex determining gene Sry that is expressed in XY, but not in XX gonads, triggering testis differentiation in male fetuses (Koopman et al. 1991; Svingen and Koopman 2013). Subsequently, the testes differentiate into compartmentalized organs comprising testis cords and an interstitial space. Fetal Leydig cells differentiate within the interstitium and become the main site of androgen synthesis necessary for development of accessory male sex organs and general masculinization of the body (Svingen and Koopman 2013). The testes also produce the peptide hormone Insulin-like factor 3 (INSL3) that is required for transabdominal testicular descent (Nef and Parada 1999), and anti-Müllerian hormone (AMH) which ensures regression of the Müllerian ducts; a paired structure that otherwise would develop into the female reproductive tract (Behringer 1994; Josso et al. 1993). In simple terms, the absence of these ‘male-centric’ factors allows for the female reproductive system to develop.

Testosterone drives masculinization

Simply put, testosterone regulates secondary sex differentiation. If testosterone is present, the body will develop male traits; if not present, the body will develop female traits (Fig. 1). However, the full picture is much more complex. First, many factors other than testosterone are involved, including AMH and INSL3 as mentioned above, but also others such as Hedgehog (Hh), Wingless-like (Wnt) and various growth factors. Second, androgen-dependent masculinization processes are likely influenced by actual hormone levels in target tissues, meaning that masculinization cannot be viewed as a simple ‘on–off’ switch, but rather a scenario, where more or less androgens can, to some degree, result in more or less masculine traits. From this viewpoint, it is more difficult to define when a morphometric change can be regarded as adverse or not. Nevertheless, as shown by Alfred Jost more than half a century ago (Jost 1947, 1953), androgens are the main drivers of male sex differentiation and are essential during a critical time window of development (MacLeod et al. 2010).

The fetal masculinization process involves numerous tissues and organs, including development of external genitalia and sex-specific differentiation of the perineum: the region between anus and genitalia (Fig. 1). In these tissues, the process seems largely governed by dihydro-testosterone (DHT) which is locally converted from testosterone by the enzyme 5α-reductase. DHT acts by binding to and activating the Androgen receptor (AR), a nuclear hormone receptor responsible for regulating transcription of target genes (Fig. 2).

It has been suggested that the AGD is masculinized during development when AR activation stimulates the growth of the perineal muscles levator ani and bulbocavernosus (LABC) complex. In males, AR is expressed in non-myo-cytic cells of the LABC (Ipulan et al. 2014). Activation of AR in these cells prompts the growth of the LABC complex and the resulting size is thought to directly affect the AGD. Indeed, ablation of AR in rodents impairs development of the LABC complex and results in feminized male AGD (Ipulan et al. 2014; MacLean et al. 2008; Notini et al. 2005).

It is likely that more subtle changes in androgen levels, as for instance seen with fetal exposure to anti-androgenic compounds, can affect AGD by the same mechanism. This is supported by rodent toxicity studies, where a short AGD is
often associated with a reduced LABC weight (Christiansen et al. 2008). There are, however, indications that effects on AGD are more complicated than just androgens stimulating muscle growth and anti-androgens that depress this. First, while AGD is thought to be relatively stable throughout life, the perineum is in fact responsive to postnatal changes in androgen levels (Kita et al. 2016; Mitchell et al. 2015). Second, certain EDCs have been found to induce both shorter
| Substance | Dose at max effects (mg/kg bw/day) | Male AGD max effect (% shorter) | Male AGDi max effect (% shorter) | Female AGD or AGDi (↑/↓) | References |
|-----------|----------------------------------|-------------------------------|-------------------------------|------------------------|------------|
| Increasing chain length (descending order) |
| DMP       | 750 n.e.                         | n.e.                          | n.e.                          | n.e.                   | Gray et al. (2000) |
| DEP       | 750 n.e.                         | n.e.                          | n.e.                          | n.e.                   | Gray et al. (2000) |
| DiBP      | 250 n.e.                         | 5                             | x                             | ↑                      | Saillenfait et al. (2017) |
|           | 600 14                           | 9                             | x                             | ↑                      | Borch et al. (2006) |
|           | 625 22                           | 6                             | x                             | ↑                      | Saillenfait et al. (2008) |
| DBP       | 500 n.e.                         | 5                             | x                             | ↑                      | Scott et al. (2007) |
|           | 500 9–14                         | 12 (Martino-Andrade)          | n.e.                          | x                      | Barlow et al. (2004), Howdeshell et al. (2007), Martino-Andrade et al. (2009) and Wolf et al. (1999) |
|           | 500 20–28                        | 21 (de Mello Santos)          | n.e.                          | x                      | Carruthers and Foster (2005), de Mello Santos et al. (2017), Mylchreest et al. (1999), Saillenfait et al. (2008), Scott et al. (2008) and Wolf et al. (1999) |
|           | ~ 640 11                         | 10                            | x                             | ↑                      | Clewell et al. (2013) |
|           | ~ 650 43                         | 26 (AGD/BW)                   | n.e.                          | x                      | Ema et al. (1998) |
|           | ~ 700 19 (increases at other doses) | x                             | n.e.                          | x                      | Lee et al. (2004) |
|           | 750 x                            | 9                             | x                             | x                      | Jiang et al. (2007) |
|           | 750 20–24                        | x                             | n.e.                          | Mylchreest             | Mylchreest et al. (1998) and van den Driesche et al. (2017) |
|           | 750 36                           | x                             | x                             | x                      | Van den Driesche et al. (2012) |
|           | 850 20                           | x                             | x                             | x                      | Jiang et al. (2011) and Liu et al. (2016) |
|           | 850 x                            | 6                             | x                             | x                      | Jiang et al. (2015b) |
|           | 900 27                           | x                             | x                             | x                      | Li et al. (2015) |
|           | 1500 48                          | 26 (AGD/BW)                   | n.e.                          | x                      | Ema et al. (2000) |
| MBuP      | 750 39                           | x                             | 29                            | n.e.                   | Ema and Miyawaki (2001) |
Table 1 (continued)

| Substance | Dose at max effects (mg/kg bw/day) | Male AGD max effect (% shorter) | Male AGDi max effect (% shorter) | Female AGD | References |
|-----------|----------------------------------|-------------------------------|-------------------------------|------------|------------|

*Increasing chain length (descending order)*

| Substance | Dose at max effects (mg/kg bw/day) | Male AGD max effect (% shorter) | Male AGDi max effect (% shorter) | Female AGD | References |
|-----------|----------------------------------|-------------------------------|-------------------------------|------------|------------|
| DEHP      | 30                               | x                             | n.e.                          | n.e.       | Christiansen et al. (2009) |
|           | 150                              | n.e.                          | n.e.                          | n.e.       | Martino-Andrade et al. (2009) |
|           | 300                              | x                             | 5                             | n.e.       | Nardelli et al. (2017) |
|           | 500                              | 10                            | x                             | x          | Howdeshell et al. (2007) |
|           | 500                              | 18                            | 18                            | x          | Saillenfait et al. (2009b) |
|           | 750                              | 17–18                         | 17 (Kita)                     | x          | Jarfelt et al. (2005), Kita et al. (2016) and Lin et al. (2009) |
|           | 750                              | 30–34                         | x                             | n.e. Gray | Gray et al. (2000) and Wolf et al. (1999) |
|           | 900                              | 14                            | x                             | x          | Christiansen et al. (2010) |
|           | 1000                             | 30                            | 11 (AGD/BW)                   | x          | Li et al. (2013) |
|           | 1500                             | 27                            | x                             | n.e.       | Moore et al. (2001) |
| DHP       | 500                              | 20                            | 23                            | x          | Aydoğan Ahbab and Barlas (2015) |
| DCHP      | ~ 350                            | 6                             | 7                             | n.e.       | Hoshino et al. (2005a) |
|           | 500                              | 27                            | 26                            | x          | Aydoğan Ahbab and Barlas (2015) |
| BBP       | 750                              | 17                            | 13                            | n.e.       | Saillenfait et al. (2009a) |
|           | 750                              | 9                             | x                             | n.e.       | Hotchkiss et al. (2004) and Nagao et al. (2000) |
|           | 750                              | 30                            | x                             | n.e.       | Tyl et al. (2004) |
|           | 1000                             | 38                            | 29                            | n.e.       | Gray et al. (2000) |
|           |                                  |                               |                               |            | Ema and Miyawaki (2002) |
| MBeP      | 375                              | 30                            | 29                            | n.e.       | Ema et al. (2003) |
| DnHP      | 500                              | 18                            | 18                            | x          | Saillenfait et al. (2009b) |
|           | 750                              | 35                            | 31                            | ↓          | Saillenfait et al. (2009a) |
| DiHP      | ~ 500                            | 15                            | x                             | n.e.       | McKee et al. (2006) |
| DHP       | 1000                             | 11                            | 10                            | n.e.       | Saillenfait et al. (2011) |
| DOTP      | 1000                             | n.e.                          | n.e.                          | x          | Saillenfait et al. (2011) |
|           | 750                              | n.e.                          | n.e.                          | n.e.       | Gray et al. (2000) |
and longer female AGD or have multiple modes of action, as will be discussed later. Thus, more research is needed to fully understand how AGD is affected by fetal endocrine disruption.

**Anogenital distance: a biomarker for fetal hormone action and late-life reproductive health**

A large number of studies now support various aspects of the ‘testicular dysgenesis syndrome’ (TDS) hypothesis. However, it has also become increasingly clear that the relationship between hormone disruption and disease outcome is not always obvious. A simple reason for this is that male reproductive disorders can arise from various causes, not least genetic mutations or even genotypic predispositions. This can, in some instances, make it difficult to prove direct cause–effect relationships between chemical exposure and disease state in humans, especially if contributing genetics is present but not characterized. Another major complication is the considerable latency between exposure and disease manifestation, for instance, with regard to reduced sperm quality; a medical condition that can also be influenced by many other factors in the years between fetal life, birth, and adulthood. Hence, a single common biomarker that can predict a number of male reproductive disorders could prove valuable, both from a scientific and clinical point of view.

**AGD measurements in human epidemiology and medicine**

Fetal exposure to EDCs has been associated with a short AGD in new-born boys. Phthalates are the most frequently reported chemicals associated with a short AGD (Adibi et al. 2015; Bornehag et al. 2015; Bustamante-Montes et al. 2013; Marshe et al. 2006; Suzuki et al. 2012; Swan et al. 2005), but also other compounds including dioxins (Vafeiadi et al. 2013), bisphenol A (Mammadov et al. 2018; Miao et al. 2011) and mild analgesics (Fisher et al. 2016; Lind et al. 2017). Notably, several studies have not found significant correlations between exposure levels and short AGD in boys, including some phthalates (Jensen et al. 2016), dichloro-diphenyl-trichloroethane (DDT) (Bornman et al. 2016), triclosan (Lassen et al. 2016), and various pesticides (Dalsager et al. 2018). These discrepancies do not necessarily diminish the cause for concern, but rather highlight the challenges of obtaining evidence for causal relationships from human epidemiological studies.

With regard to reproductive disorders, many studies have reported significant correlations between short AGD in boys and for instance hypospadias (Cox et al. 2017; Gilboa et al. 2017; Hsieh et al. 2012; Singal et al. 2016),
Table 2  Summary of rat toxicity studies reporting on AGD measurements following gestational exposure to compounds other than phthalates

| Substance     | Dose at max effects (mg/kg bw/day) | Male AGD max effect (% shorter) | Male AGDi max effect (% shorter) | Female AGD or AGDi (↑↓) | References |
|---------------|-----------------------------------|---------------------------------|----------------------------------|-------------------------|------------|
| **Drugs**     |                                   |                                 |                                  |                         |            |
| Acetylsalicylic acid | 400 | 38 | x | n.e. | Gupta and Goldman (1986) |
| Aniline       | 93 | x | 20 | x | Holm et al. (2015) (mouse study) |
| Paracetamol   | 150 | 9\(^a\) | 10.5\(^a\) | x | Kristensen et al. (2011) |
|               | 150 | x | 15 | x | Holm et al. (2015) (mouse study) |
|               | 350 | 8 | 9 | x | van den Driesche et al. (2015) |
|               | 360 | x | n.e. | n.e. | Axelstad et al. (2014) |
| Dexamethasone | 0.1 | 10 | x | x | Van den Driesche et al. (2012) |
| Finasteride   | 0.1 | x | 9 | x | Christiansen et al. (2009) |
|               | 100 | 33 | x | x | Bowman et al. (2003) |
| Flutamide     | 16–20 | 44\(^{Kita}\) | 41–42 | x | Hass et al. (2007); Kita et al. (2016) |
|               | 50 | 16–53 | x | x | Foster and Harris (2005) and McIntyre et al. (2001) |
|               | 100 | 33–55 | x | x | Mylchreest et al. (1999), Scott et al. (2007) and Welsh et al. (2007) |
| Ethinyl estradiol | (0.00–0.05) | n.e. | n.e. | (↑\(^{Mandrup}\)) Ferguson et al. (2011), Howdeshell et al. (2008) and Mandrup et al. (2013) |
| Ketoeconazole | (50) | n.e. | x | x | Wolf et al. (1999) |
|               | 50 | 8 | 11 | ↓ | Taxvig et al. (2008) |
| **Pesticides** |                                   |                                 |                                  |                         |            |
| Epoxiconazole | 3.75 | 5\(^a\) | 5\(^a\) | ↑ | Hass et al. (2012) |
|               | 15 | γ\(_{PND0}\)^a | 10\(_{GD21}\)^a | ↑ | Taxvig et al. (2007) |
|               | 50 | n.e. | n.e. | n.e. | Taxvig et al. (2008) |
| Myclobutanil  | 145 | 1\(^{increased}\) | x | x | Goetz et al. (2007) |
| Prochloraz    | (0.01–35) | n.e. | x | (↑\(^{Melching,Hase}\)) Christiansen et al. (2009), Hass et al. (2012), Melching-Kollmuss et al. (2017) and Vinggaard et al. (2005) |
|               | 150 | x | 12 | ↑ | Later et al. (2006) |
|               | 250 | 6 | x | ↑ | Noriega et al. (2005) |
| Propiconazole | 50 | n.e. | n.e. | n.e. | Taxvig et al. (2008) |
|               | ~158 | 8\(^{increased}\) | x | x | Goetz et al. (2007) |
| Tebuconazole  | 12.5–50 | n.e. | n.e. | (↑\(^{Hass}\)) Hass et al. (2012) and Taxvig et al. (2008) |
|               | 100 | n.e. | 10\(^{increased (only at GD21)}\) | ↑ | Taxvig et al. (2007) |
| **Pesticides** |                                   |                                 |                                  |                         |            |
| Triadimefon   | ~114 | 3\(^{increased}\) | x | x | Goetz et al. (2007) |
| Mancozeb      | 25 | n.e. | n.e. | n.e. | Hass et al. (2012) |
| Vinclozolin   | 12 | n.e. | n.e. | n.e. | Colbert et al. (2005) |
|               | 50–60 | 2\(^{Matsuura}\) | 9–21 | n.e. \(^{Matsuura}\) Christiansen et al. (2009) and Matsuura et al. (2005a) |
|               | ~100 | 28 | 22 | x | Schneider et al. (2011) |
|               | 100 | 28 | x | x | Ostby et al. (1999) |
|               | 160 | x | 35 | x | Hass et al. (2007) |
|               | 200 | 46–56 | x | (↓\(^{Gray}\)) Gray et al. (1994) and Wolf et al. (2004) |
| Procymidone   | 50 | 10 | 9 | n.e. | Hass et al. (2012) |
|               | 100 | 24 | n.e. | x | Wolf et al. (1999) |
|               | 150 | x | 37 | x | Hass et al. (2007) |
cryptorchidism (Jain and Singal 2013; Jiang et al. 2015a), penile length (Alaee et al. 2014; Thankamony et al. 2014), and sperm quality (Eisenberg et al. 2012; Mendiola et al. 2011). Together, these observations fit the model of a common ‘fetal origin of disease’, with androgen disruption at the root of the problem. However, they cannot provide definite proof for cause–effect relationships. There is also the complications of accounting for genetic variations of the fetus or maternal characteristics such as parity, factors that themselves can influence the AGD (Barrett et al. 2014; Eisenberg et al. 2013). This ultimately means that two individuals being exposed to the same chemicals could respond differently and display variable degree of changes to the AGD. Because of all these complexities with interpreting human data, the rodent models can be used to provide more robust causative evidence.

### AGD measurements in rodent studies

In rats, a short AGD in male offspring after fetal exposure to anti-androgenic compounds often correlates with various reproductive disorders (Bowman et al. 2003; Christiansen et al. 2008; Welsh et al. 2008, 2010). There is evidence to suggest that the more pronounced the effect on the AGD, the more likely additional reproductive defects such as genital malformations are found (Christiansen et al. 2008). However, there is not always a clear correlation between the severity of AGD effects and severity or frequency of other reproductive malformations, such that AGD cannot always stand on its own in the prediction of perceived anti-androgenic effects.

High-exposure studies have reported on male pups with ‘female-like’ AGD, where male AGD in exposed offspring is

---

**Table 2**

| Substance         | Dose at max effects (mg/kg bw/day) | Male AGD max effect (% shorter) | Male AGDi max effect (% shorter) | Female AGD or AGDi (↑/↓) | References |
|-------------------|-----------------------------------|--------------------------------|---------------------------------|--------------------------|------------|
| Linuron           | 50                                | Not sig. in 2000                | x                               | n.e. (2002)              | McIntyre et al. (2000) and McIntyre et al. (2000) |
|                   | 75–100                            | 25–31                           | x                               | x                        | Hotchkiss et al. (2004) and Wolf et al. (1999)          |
| p,p′-DDE          | 100                               | 6–9                             | x                               | x                        | Wolf et al. (1999)                                      |
|                   | 50–200                            | x                               | 11 (AGD/crown–rump length)      | x                        | Loeffler and Peterson (1999)                            |
| Fenitrothion      | 25                                | 16                              | x                               | n.e.                     | Turner et al. (2002)                                   |
| Lindane           | −16                               | n.e.                            | n.e.                            | (↓)                      | Matsuura et al. (2005b)                                 |
| Methoxychlor      | −82                               | n.e.                            | x                               | n.e.                     | Masutomi et al. (2003)                                 |
| UV filters        |                                   |                                 |                                 |                          |            |
| Benzophenone      | (−130)                            | n.e.                            | n.e.                            | ↓                        | Hoshino et al. (2005b)                                  |
| HBM               | (−3250)                           | x                               | n.e.                            | n.e.                     | Nakamura et al. (2015)                                 |
| OMC               | (1000)                            | n.e.                            | n.e.                            | n.e.                     | Axelstad et al. (2011)                                 |
| Butylparaben      | 500                               | 7                               | 6                               | ↓                        | Boberg et al. (2016)                                   |
|                   | 600                               | n.e.                            | n.e.                            | n.e.                     | Boberg et al. (2008)                                   |
|                   | 1000                              | 16                              | x                               | x                        | Zhang et al. (2014)                                    |
| Plastic additive |                                   |                                 |                                 |                          |            |
| Bisphenol A       | 0.25                              | 7                               | x                               | n.e.                     | Christiansen et al. (2014)                             |
|                   | (0.0025–50)                       | n.e.                            | n.e.                            | (Ferguson, Tinwell)      | Ferguson et al. (2011), Howdeshell et al. (2008) and Tinwell et al. (2002) |
|                   | (5–385)                           | n.e.                            | x                               | n.e.                     | Takagi et al. (2004)                                   |
| Nonylphenol       | (−250)                            | n.e.                            | n.e.                            | ↓                        | Takagi et al. (2004)                                   |
| Genistein         | −67                               | n.e.                            | x                               | n.e.                     | Masutomi et al. (2003)                                 |
| Other             |                                   |                                 |                                 |                          |            |
| TCDD              | 0.1                               | 6–12                            | Not sig. when BW or CR length taken into account | x | x | Bjerke and Peterson (1994) and Gray et al. (1995) |

AGD data after in utero exposure to various substances and the dose at which maximum shorter mean AGD was observed. In many instances, percentage shorter AGD was estimated from published graphs, as raw data were not available. A more complete compilation of data is found in Suppl. Table S1.

x not assessed, n.e. no effect, ↑ longer female AGD or AGDi, ↓ shorter female AGD or AGDi, DDE DDT metabolite, dichloro-diphenyl-dichloro-ethylene, TCDD 2,3,7,8-tetrachlorodibenzo-p-dioxin, HBM 2-hydroxy-4-methoxybenzone, OMC octyl methoxycinnamate

*a*Non-monotonic (low-dose) effect
close to 50% that of control males. This does not only make the sex of the offspring difficult to determine (Christiansen et al. 2010; Hass et al. 2007; Ostby et al. 1999; Parks et al. 2000), but also result in additional phenotypes including nipple retention, genital malformations, and reduced reproductive organ weights (Bowman et al. 2003; Christiansen et al. 2008; Welsh et al. 2008, 2010). These reproductive phenotypes are all, at least to some degree, under androgen control during fetal development, making AGD a potentially robust marker for anti-androgenic effects.

AGD in animal toxicity studies: phthalates

The group of compounds most frequently reported to affect male AGD is the phthalate esters. As summarized in Table 1, many different phthalates have been tested in rats, with dibutyl phthalate (DBP) and diethylhexyl phthalate (DEHP) being the most prevalent. From an early rat study on DEHP showing testicular toxicity (Gray et al. 1977) and structure–activity relationships suggesting linear side-chain esters of 4–6 carbons to be of specific concern (Foster et al. 1980), numerous toxicity studies on phthalates followed, providing increasing evidence for what later has been termed the ‘phthalate syndrome’ [(Foster 2006) and Table 1].

Fetal exposure to certain phthalates (chain length C4–C6) results in a short AGD in rat male offspring, without any significant effect on female AGD (Table 1). It is, for the most part, a dose-dependent effect, where increasing dose levels result in progressively shorter AGD. Notably, the magnitude of AGD effects can differ greatly between studies, probably influenced by parameters such as rat strain, group size, or method used for AGD measurements. Body weights may also influence AGD measurements, but are unfortunately not always accounted for. In developmental toxicity studies, the offspring’s body weight is in fact frequently affected, particularly at higher exposure levels (Gallavan et al. 1999). Since the AGD correlates with the size of the fetus or newborn pup, body weight should ideally be accounted for by calculating the AGDi, or by including body weight as a covariate in the statistical analysis. Unfortunately, this is not always done, as indicated in Tables 1 and 2. This means that a significantly short AGD in many instances may not be bona fide feminization effect, but rather a readout of stunted growth. To remedy this problem for risk-assessment purposes, OECD test guidelines and guidance documents stipulate that bodyweight measurements must be included alongside AGD measurements (guidance documents 151 and 43), as discussed in “AGD measurements in regulatory toxicology”.

From the studies listed in Table 1, the most pronounced effect on AGD was seen for DBP at a dose of 1500 mg/kg/day. At this high perinatal exposure level, the average male AGD was 48% shorter than normal, but when accounting for pup body weight, the adjusted value (AGDi) was...
needed to devise the best test strategies for the future. The events that are both similar and different between species is sures. However, more detailed knowledge about molecular against detrimental effects in the wake of intrauterine expo- 

would be that since the rat seems to be the most sensitive androgenic effects remains uncertain. The best argument these discrepancies for using AGD as a biomarker for anti-

networks such as pituitary hormones. The implication of is not simply caused by direct disruption of steroidogenesis, at least in some instances, disruption to testosterone output (Svechnikov et al. 2016). These observations indicate that early developmental stages, but suppress at late gesta- 

the lowest dose, supporting the use of AGD as a sensitive biomarker for these compounds. Rat Leydig cells appear more sensitive to phthalate dis- 

Rat Leydig cells appear more sensitive to phthalate disrup- 

ch. For instance, the phthalate esters DEHP, MEHP, and DBP reportedly elevate testosterone levels in mice at early developmental stages, but suppress at late gestation, whereas no effects are observed in human fetal testis explants, with or without luteinizing hormone (LH) stimulation. Yet, in cultured mouse Leydig cells, MEHP can both inhibit and stimulate steroidogenesis depending on cell line (Svechnikov et al. 2016). These observations indicate that at least in some instances, disruption to testosterone output is not simply caused by direct disruption of steroidogenesis, or Leydig cells, but likely also includes endocrine signaling networks such as pituitary hormones. The implication of these discrepancies for using AGD as a biomarker for anti-androgenic effects remains uncertain. The best argument would be that since the rat seems to be the most sensitive model, it has the highest potential for safeguarding humans against detrimental effects in the wake of intrauterine exposures. However, more detailed knowledge about molecular events that are both similar and different between species is needed to devise the best test strategies for the future. The human relevance of rodent AGD data could then potentially be confirmed by testing chemicals in human-based cell and tissue systems.

**AGD in animal toxicity studies: miscellaneous compounds**

As summarized in Table 2, various substances from diverse chemical classes can affect the AGD in rat offspring. These include compounds with a clear anti-androgenic mode of action that cause even more severe effects on AGD than the potent anti-androgenic phthalates.

Prenatal exposure to high doses of certain AR antagonists completely feminizes the male pup AGD to 50% that of control males. This is the case for the pesticide procy- 

midone, vinclozolin, and the non-steroidal prostate cancer drug flutamide (Christiansen et al. 2008; Hass et al. 2007; Ostby et al. 1999; Parks et al. 2000). After exposure to these compounds, the male offspring also displays an increased rate of nipple retention, high incidence of genital malforma-

Of note, for several of the listed compounds the relationship between chemical exposure and AGD does not always follow a continuous pattern, where reduction in the AGD index is proportional to exposure levels, or concomitant reproductive abnormalities.

Fetal exposure to both the antimicrobial preservative butyl paraben (Boberg et al. 2016; Zhang et al. 2014) and the industrial plasticizer bisphenol A (Christiansen et al. 2014) has been shown to shorten the male AGD around 7–16% in the male offspring, albeit there are studies reporting no effects on AGD for both butyl paraben (Boberg et al. 2008) and bisphenol A (Ferguson et al. 2011; Howdeshell et al. 2008; Takagi et al. 2004; Tinwell et al. 2002). In the cases where short AGD was observed with these compounds, clear effects on nipple retention or genital malformations were rarely seen. On the other hand, decreased sperm count or affected prostate development were observed, as were disrupted mammary glands in female offspring (Boberg et al. 2016; Hass et al. 2016; Mandrup et al. 2016). The intuitively appealing explanation for these discrepancies in phenotypic manifestations is that the latter compounds are considered mainly estrogenic. However, they also display weak anti-androgenic potential in vitro (Chen et al. 2007; Reif et al. 2010; Rosenmai et al. 2014; Satoh et al. 2005) and show effect in several in vitro toxicity assays for other mechani-

misms of action according to Toxicity Forecast [ToxCast; a program developed by the US Environmental Protection Agency to predict hazards and prioritize toxicity testing of environmental chemicals (Dix et al. 2007)]. This leaves the question of whether this small effect on AGD is the result of a weak anti-androgenic or an estrogenic effect, or yet another mechanism of action.

Fetal exposure to the estrogenic compound ethinyl estradiol does not seem to affect AGD in male offspring (Ferguson et al. 2012; Howdeshell et al. 2008; Mandrup et al. 2013), which then argue against the observed effect on male AGD following exposure to butyl paraben or BPA being estrogenic. It appears more likely that there are some weaker anti-androgenic effects exerted by these compounds.
that do not increase significantly in efficacy at increasing doses. Another explanation could be lent from observations that estrogenic compounds can reduce the ability of Leydig cells to synthesize testosterone, as reviewed elsewhere (Svetchnikov et al. 2010). A recent study where mice were exposed to diethylstilbestrol (DES) also resulted in a short AGD in male offspring, again hypothesized to be caused by reduced testosterone production (Stewart et al. 2018). This is in agreement with what has been observed in rats following exposure to high doses of estrogens, where AR expression is lost in all tissues that show ‘anti-androgenic’ effects, as well as a reduction in Leydig cell numbers (Williams et al. 2001). Nevertheless, more mechanistic insight is required to fully explain how estrogenic compounds give rise to seemingly anti-androgenic effects.

Another group of chemicals that can elicit effects on reproductive development, including AGD, is the azole fungicides. They are used by both the medical and agricultural industries for their anti-fungal properties. They can, however, provoke side effects in humans and are known to primarily interfere with CYP-family enzymes (Ashley et al. 2006), but also nuclear receptors (Dreisig et al. 2013). As shown in Table 2, there are six azoles that in some studies have been shown to affect the AGD in rats: the drug ketoconazole, and the pesticides epoxiconazole, myclobutanil, prochloraz, propiconazole, and tebuconazole. At tested doses, they do not cause large changes to AGD, but strikingly, many of them cause longer rather than shorter AGD in male offspring. This is not the case for ketoconazole, however, where fetal exposure to 50 mg/kg resulted in around 8–11% shorter male AGD (Taxvig et al. 2008). Notably, a contradictory study has reported no effect on AGD after exposure to ketoconazole at a similarly high dose (Wolf et al. 1999).

Prochloraz is an imidazole fungicide that can cause various adverse effects in rat fetuses at high doses. Regarding reproductive effects, prochloraz exposure can induce nipple retention in male offspring (Christiansen et al. 2009; Vinggaard et al. 2005), whereas effects on AGD are conflicting between studies. If taking birth-weight into account, there were no significant effects on male AGD at doses similar to those causing nipple retention (25–150 mg/kg) (Christiansen et al. 2009; Melching-Kollmuss et al. 2017; Noriega et al. 2005; Vinggaard et al. 2005). Another study reported around 10% shorter male AGD after fetal exposure to high doses of prochloraz concomitant with nipple retention at the same doses (Laier et al. 2006). Screening studies have shown that prochloraz can provoke multiple mechanisms of action in vitro, as it antagonizes the androgen and the estrogen receptor, agonizes the Ah receptor, and inhibits aromatase activity (Vinggaard et al. 2006). Whether or not all these mechanisms are activated in vivo, and what effects this would have on the developing fetus, remains to be properly clarified.

Exposure to myclobutanil, propiconazole, and tebuconazole can all seemingly induce longer AGD in male offspring, whereas with epoxiconazole, the picture is less clear with only weak indications that it may affect AGD (Goetz et al. 2007; Hass et al. 2012; Taxvig et al. 2007). By what mechanisms this occurs remains unclear. Taken together, however, the azole fungicides seem to elicit different effects on the developing fetus, resulting in effect outcomes not readily explained due to our limited knowledge about mechanisms and modalities, which should be a focus area for future studies.

**Note on mild analgesics and their endocrine disrupting properties**

Non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol/acetaminophen represent a group of mild analgesics suggested to have endocrine disrupting properties. As recently reviewed (Kristensen et al. 2016), their use across the world has risen dramatically in recent years. Herein, we will not discuss in great detail the potential endocrine effects from the analgesics, but highlight studies where effects on AGD have been reported.

Fetal exposure to therapeutically relevant doses of paracetamol can result in 5–10% reduction in male rat AGDi (Kristensen et al. 2011). Another study using a similar high dose and exposure regimen failed to show a statistically significant change to male AGDi, but here, significant effects on nipple retention and reduction in LABC muscle complex weight were observed (Axelstad et al. 2014). Effects on AGD have also been observed in mice after in utero exposure to mild analgesics, and already in 1986, it was shown that male fetuses exposed to aspirin or indomethacin could present with shorter than normal AGD (Gupta and Goldman 1986). More recently, exposure to both aniline (which is metabolized to paracetamol in vivo) and paracetamol during pregnancy resulted in short AGD in male offspring (Holm et al. 2015). Although these studies strongly suggest that the mild analgesics act as anti-androgenic agents in the male fetuses, there are still not enough mechanistic studies available that convincingly support this conclusion.

**Is AGD a useful biomarker for female reproduction?**

In females, a longer AGD is considered a masculinization effect, something that would result from the presence of excess androgen levels or ectopic activation of AR. For example, longer than normal female AGD is associated with elevated testosterone levels (Mira-Escolano et al. 2014), exemplified by daughters born of women with polycystic ovarian syndrome (Barrett et al. 2018; Wu et al. 2017).
These clinical observations are further supported by rat studies (Hotchkiss et al. 2007; Ostby and Gray 2004; Ramezani Tehrani et al. 2014; Wolf et al. 2002), and are in line with what we know about how androgens masculinize fetal tissues. However, other mechanisms have also been proposed to underpin masculinization of female fetuses, for instance, ectopic activation of the progesterone receptor (PR).

The fungicide vinclozolin has been suggested to masculinize mouse female fetuses by activation of the PR, further supported by the fact that the synthetic progestrone medroxyprogesterone acetate also masculinizes the female offspring (Buckley et al. 2006). Notably, fetal exposure in rats had no significant effect on female AGD (Hass et al. 2007). Nevertheless, although synthetic progestrones can activate the PR, many synthetic progestins such as medroxyprogesterone also targets other nuclear receptors and can give rise to many off-target effects (Kuhl 2005). For instance, progestins were widely used to prevent miscarriage in the 1950s and 60s, but proved to masculinize the external genitalia of the female offspring (Money and Mathews 1982), and initially referred to as progestin-induced hermaphroditism (Wilkins et al. 1958). Even if these effects seem to be driven by PR-mediated signaling, it cannot be excluded that androgenic modes of action are involved. Not only are several progestins, including medroxyprogesterone, androgenic (Kuhl 2005), but androgen levels can seemingly also be elevated by high levels of progesters, ultimately giving rise to androgenic effects (Auchus and Chang 2010).

Female rats exposed to the azole fungicide prochloraz present with longer AGD at birth, concomitant with elevated progesterone levels (Laier et al. 2006; Melching-Kollmuss et al. 2017). Prochloraz can induce progesterone synthesis in vitro by CYP17 inhibition at concentrations above 10 nM (Dreisig et al. 2013), a mechanism confirmed in vivo, where fetal plasma concentrations were measured at 24 nM following maternal exposure to 150 mg/kg bw/day of prochloraz (Laier et al. 2006). Although this does not prove that progesterone was acting via the PR to induce masculinization, androgen levels were not elevated in the same animals and hence suggest that this is an alternative mechanism, since azoles themselves do not seem to activate the AR. A definitive answer remains elusive, however, and much work remains to be done on azoles to characterize their sometimes perplexing modes of action.

Estrogens can seemingly also cause longer AGD in females. Although fetal exposure to ethinyl estradiol does not affect male AGD in rats, female offspring can present with longer AGD following exposure to supra-physiologically doses (Casanova et al. 1999; Delclos et al. 2009; Mandrup et al. 2013; NTP 2010; Ryan et al. 2010; Sawaki et al. 2003). Immediately, this effect seems counter-intuitive; however, very high doses of steroidal estrogens can agonize the AR (Vinggaard et al. 1999), which suggests that the effects are driven by androgen action rather than being estrogenic.

There are also examples, where female AGD is shorter than normal following in utero exposure, observations that evoke more questions than answers. The types of compounds capable of shortening female AGD in rodent are also variable and include bisphenol A (Christiansen et al. 2014), butyl phthalate (Boberg et al. 2016), ketoconazole (Taxvig et al. 2008), paracetamol (Holm et al. 2016), as well as di-n-hexyl phthalate and dicyclohexyl phthalate (Aydoğan Ahbab and Barlas 2015). These studies are not covered in detail herein, and thus not presented with proper weight of evidence as yet any plausible mechanisms- or modes of action are lacking. It would, however, be of great interest to design studies specifically to answer such questions, as they may reveal insights of value to perineal development more broadly.

### AGD measurements in regulatory toxicology

#### AGD in chemical risk assessment

Within a regulatory context, AGD measurements are mandatory to perform at either gestational days 20–21 or postnatal days 0–4 in several OECD test guidelines used to test for developmental and reproductive toxicity in chemical risk assessment. These guidelines include the extended one generation study (TG 443), the two reproductive toxicity screening studies (TG 421/422) and the newly updated TG 414 Developmental toxicity study (OECD 2012, 2016a, b, 2018). The OECD guidance documents (OECD GD 43 and GD 151), which guides the interpretation of these guidelines, states that “A statistically significant change in AGD that cannot be explained by the size of the animal indicates effects of the exposure and should be considered in setting the NOAEL (No Observed Adverse Effect Level)” (OECD 2008, 2013). This means that, when a statistically significant shorter AGD in male rat offspring is considered the critical effect, a NOAEL can be based on this information and used as the point of departure for setting safe exposure levels for humans. Since AGD measurements will be included as an endpoint when performing almost all future regulatory studies investigating developmental and reproductive toxicity, it will improve on the sensitivity for identifying endocrine disruptors and developmental toxicants in mammals. In addition, this inclusion will generate much data, which will contribute to more thorough evaluations of substances and information pertaining to their modes of action.

#### Other morphological biomarkers to support AGD

Nipples and mammary glands originate from bipotential structures that develop differentially between the sexes in response to specific molecular cues. In humans, both sexes are born with a pair of nipples and breast development in
In the developing male rodent, the presence of DHT causes regression, or apoptosis of the nipple anlagen (Imperato-McGinley et al. 1986). This process is blocked by fetal exposure to anti-androgens, and these male offspring subsequently display nipples similarly to their female littermates. Therefore, nipple retention in male pups is used alongside AGD as a morphometric marker of impaired androgen action. Although this morphological phenomenon does not occur in humans, it can, nevertheless, be used to predict anti-androgenic effects of chemicals. In other words, the fact that nipples are retained in exposed male rat offspring can be used to predict reproductive disorders caused by chemical exposures, even though nipples do not regress in human males. Whether AGD or nipple retention possess similar sensitivity, as was recently shown for an 18-chemical mixture of anti-androgens (Conley et al. 2018), or if one of the endpoints is more sensitive than the other, seems to depend on what chemical is being tested. Therefore, inclusion of both AGD and nipple retention in reproductive toxicity studies, in a weight-of-evidence manner, can significantly improve on the assessment of potential EDCs (OECD 2015). Nipple retention is also mandatory to assess in three separate OECD test guidelines (TG 443, TG 421/422).

Conclusions and perspectives

AGD has emerged a useful biomarker to detect fetal androgen insufficiency and is now applied in regulatory testing strategies for detecting endocrine disrupting effects. Its utility in a clinical setting is less defined, but it has received more traction in the last few years. It is our conviction that it will remain a standard retrospective biomarker in rodent toxicity studies and risk assessment. In humans, it will increasingly serve as a prospective biomarker, where a shorter than normal AGD in male offspring will be a warning flag for future reproductive complications, not least fertility issues. For this to fully eventuate, however, much more research focusing on answering many knowledge gaps is required. To this end, we would emphasize four areas that we believe should be focused on in the near future.

First, more efforts should be channelled into characterizing the morphoregulatory pathways of perineal development. Although the current dogma stipulates that the length of the AGD is controlled by the level of androgen action during the ‘masculinization programming window’, other regulatory pathways also seem to play a role, at the very least as effect-outcome modifiers.

Second, there is a need to better define the relationship between anti-androgenic effects and the length of the male AGD, both in rodents and humans. Should we rely purely on ‘statistically significant’ differences, or should a minimum percentage shorter than control mean be defined? And more importantly, can the magnitude of shortening be used to define magnitude of lost androgen action or future risk of contracting reproductive disease?

Third, to what extent can AGD measurements be used as a stand-alone biomarker to detect anti-androgenic effects in toxicity studies, and where do we need to supplement with additional effect measures? In a weight-of-evidence approach—which is currently recommended—what other measurements should be included, and when? For these evaluations, there should also be stronger emphasis on effect doses and to what extent supra-high doses reliably recapitulates what occurs at more human relevant doses. This latter point seems more important in view of chemicals that do not result in clear monotonic dose–response relationships.

Fourth, can AGD measurements be used as a biomarker in females? Certain perturbations can affect female AGD in either direction, but what does a long or short AGD really measure in female offspring? And is it linked to adverse health effects later in life? Concerning a longer than normal AGD, it would most often, if not always, be a sign of masculinization effects comparable to those observed when female fetuses receives too much androgens. With a shorter AGD, however, the jury is still out.

Acknowledgements This work was partly funded by Grants from the Danish Food and Veterinary Agency and the Independent Research Fund Denmark (DFF-6108-00114).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest pertaining to this work.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Adibi JJ, Lee MK, Naimi AI, Barrett E, Nguyen RH, Sathyanarayana S, Zhao Y, Thiet MP, Redmon JB, Swan SH (2015) Human chorionic gonadotropin partially mediates phthalate association with male and female anogenital distance. J Clin Endocrinol Metab 100(9):E1216–E1224. https://doi.org/10.1210/jc.2015-2370

Alaee E, Gharib MJ, Fouladinejad M (2014) Penile length and anogenital distance in male newborns from different Iranian ethnicities
in golestan province. Iran Red Crescent Med J 16(12):e16729. https://doi.org/10.5812/ircmj.16729

Ashley ESD, Lewis R, Lewis JS, Martin C, Andes D (2006) Pharmacology of systemic antifungal agents. Clin Infect Dis 43(Supplement_1):S28–S39. https://doi.org/10.1086/504492

Auchus RJ, Chang AY (2010) 46, XX DSD: the masculinised female. Best Pract Res Clin Endocrinol Metab 24(2):219–242. https://doi.org/10.1016/j.beem.2009.11.001

Axelstad M, Boberg J, Hougaard KS, Christiansen S, Jacobsen PR, Metzdorff SB, Hass U (2010) Low-dose perinatal exposure to di-n-butyl phthalate has comparable anti-androgenic effects to di-n-butyl phthalate. Reprod Toxicol 30(2):313–321. https://doi.org/10.1016/j.reprotox.2010.04.005

Bermen MS, Chevrier J, Rauch S, Crause M, Obida M, Sathyanarayana S, Barr DB, Eskenazi B (2016) Dichlorodiphenyltrichloroethane exposure and anogenital distance in the Venda Health Examination of Mothers, Babies and their Environment (VHEMBE) birth cohort study, South Africa. Andrology 4(4):608–615. https://doi.org/10.1111/and.12235

Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM (2003) Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci 74(2):393–406. https://doi.org/10.1093/toxsci/kfg128

Buckley J, Willingham E, Agras K, Baskin LS (2006) Embryonic exposure to the fungicide vinclozolin causes virilization of females and alteration of progesterone receptor expression in vivo: an experimental study in mice. Environ Health 5:4. https://doi.org/10.1186/1476-069X-5-4

Bustamante-Montes LP, Hernández-Valero MA, Flores-Pimentel D, García-Fábila M, Amaya-Chávez A, Barr DB, Borja-Aburto VH (2013) Prenatal exposure to phthalates is associated with decreased anogenital distance and penile size in male newborns. J Dev Orig Health Dis 4(4):300–306. https://doi.org/10.1007/s12561-012-0061-3

Carruthers CM, Foster PM (2005) Critical window of male reproductive tract development in rats following gestational exposure to di-n-butyl phthalate. Birth Defects Res B Dev Reprod Toxicol 74(3):277–285. https://doi.org/10.1002/bdrb.20050

Casanova M, You L, Guido KW, Archibegue-Engle S, Janszen DB, Heck HA (1999) Developmental effects of dietary phytoestrogens in Sprague-Dawley rats and interactions of genistein and daidzein with rat estrogen receptors alpha and beta in vitro. Toxicol Sci 51(2):236–244. https://doi.org/10.1093/toxsci/ki1.2.236

Chen J, Ahn KC, Gee NA, Gee SJ, Hammock BD, Lasley BL (2007) Antiandrogenic properties of parabens and other phenolic containing small molecules in personal care products. Toxicol Appl Pharmacol 221(3):278–284. https://doi.org/10.1016/j.taap.2007.03.015

Christiansen S, Scholze M, Axelstad M, Bøberg J, Kortenkamp A, Hass U (2008) Combined exposure to anti-androgens causes markedly increased frequencies of hypospadias in the rat. Int J Androl 31(2):241–248. https://doi.org/10.1111/j.1365-2605.2008.00866.x

Christiansen S, Scholze M, Dalgaard M, Vinggaard AM, Axelstad M, Kortenkamp A, Hass U (2009) Synergistic disruption of external male sexual differentiation by a mixture of four antiandrogens. Environ Health Perspect 117(12):1839–1846. https://doi.org/10.1289/ehp.0900689

Christiansen S, Bøberg J, Axelstad M, Dalgaard M, Vinggaard AM, Metzdorff SB, Hass U (2010) Low-dose perinatal exposure to di(2-ethylhexyl) phthalate induces anti-androgenic effects in male rats. Reprod Toxicol 30(2):313–321. https://doi.org/10.1016/j.reprotox.2010.04.005

Christiansen S, Axelstad M, Bøberg J, Vinggaard AM, Pedersen GA, Hass U (2014) Low-dose effects of bisphenol A on early sexual development in male and female rats. Reproduction 147(4):477–487. https://doi.org/10.1530/REP-13-0377

Clewell RA, Thomas A, Wilson G, Creasy DM, Andersen ME (2013) A dose response study to assess effects after dietary administration of diisononyl phthalate (DINP) in gestation and lactation on male rat sexual development. Reprod Toxicol 35:70–80. https://doi.org/10.1016/j.reprotox.2012.07.008

Colbert NK, Pelletier NC, Cote JM, Concannon JB, Jurdak NA, Minott SB, Markowski VP (2005) Perinatal exposure to low levels of the environmental antiandrogen vinclozolin alters sex-differentiated social play and sexual behaviors in the rat. Environ Health Perspect 123(1):101–107. https://doi.org/10.1289/ehp.1408163
Food Cosmet Toxicol 15(5):389–399. https://doi.org/10.1016/S0015-6264(77)80003-5

Gray LEJ, Ostby JS, Kelce WR (1994) Developmental effects of an environmental antiandrogen: the fungicide vinclozolina alters sex differentiation of the male rat. Toxicol Appl Pharmacol 129(1):46–52. https://doi.org/10.1006/tapp.1994.1227

Gupta C, Goldman AS (1986) The arachidonic acid cascade is involved in the masculinizing action of testosterone on embryonic external genitalia in mice. Proc Natl Acad Sci USA 83(12):4346–4349. https://doi.org/10.1073/pnas.83.12.4346

Hass U, Scholze M, Christiansen S, Dalgaa M, Vinggaard AM, Axelstad M, Metzendorf SB, Kortenkamp A (2007) Combined exposure to anti-androgens exacerbates disruption of sexual differentiation in the rat. Environ Health Perspect 115(Suppl 1):122–128. https://doi.org/10.1289/ehp.9360

Hass U, Boberg J, Christiansen S, Jacobsen PR, Vinggaard AM, Taxvig C, Poulsen ME, Herrmann SS, Jensen BH, Petersen A, Clemmensen LH, Axelstad M (2012) Adverse effects on sexual development in rat offspring after low dose exposure to a mixture of endocrine disrupting pesticides. Reprod Toxicol 34(2):261–274. https://doi.org/10.1016/j.reprotox.2012.05.090

Hass U, Christiansen S, Boberg J, Rasmussen MG, Mandrup K, Axelstad M (2016) Low-dose effect of developmental bisphenol A exposure on sperm count and behave in rats. Andrology 4(4):594–607. https://doi.org/10.1111/andr.12176

Holm JB, Chalmye C, Modick H, Jensen LS, Dierkes G, Weiss T, Jensen BA, Norregard MM, Borkowski K, Styrische B, Martin Koch H, Mazaad-Guitto S, Jegou B, Kristiansen K et al. (2015) Anilin Is rapidly converted into paracetamol impairing male reproductive development. Toxicol Sci 148(1):288–298. https://doi.org/10.1093/toxsci/kfv179

Holm JB, Mazaad-Guitto S, Danneskiold-Samsøe NB, Chalmye C, Jensen B, Norregard MM, Hansen CH, Styrische B, Svingen T, Vinggaard AM, Koch HM, Bowles J, Koopman P, Jégou B et al. (2016) Intruterine exposure to paracetamol and anilin impairs female reproductive development by reducing follicle reserves and fertility. Toxicol Sci 150(1):178–189. https://doi.org/10.1093/toxsci/kfs332

Hoshino N, Iwai M, Okazaki Y (2005a) A two-generation reproductive toxicity study of diclofenchyl phthalate in rats. J Toxicol Sci 30(Spec No):79–96. https://doi.org/10.2131/jts.30.579

Hoshino N, Tani E, Wako Y, Takahashi K (2005b) A two-generation reproductive toxicity study of benzophenone in rats. J Toxicol Sci 30(Spec No):5–20. https://doi.org/10.2131/jts.30.S5

Hotchkiss AK, Parks-Saldutti LG, Ostby JS, Lambright C, Furr J, Van denbergh JG, Gray LEJ (2004) A mixture of the “antiandrogens” linuron and butyl benzyl phthalate alters sexual differentiation of the male rat in a cumulative fashion. Biol Reprod 71(6):1852–1861. https://doi.org/10.1095/biolreprod.104.031674

Hotchkiss AK, Lambright CS, Ostby JS, Parks-Saldutti L, Vandenbergh JG, Gray LEJ (2007) Prenatal testosterone exposure permanently masculinizes anogenital distance, nipple development, and reproductive tract morphology in female Sprague-Dawley rats. Toxicol Sci 96(2):335–345. https://doi.org/10.1093/toxsci/ktm002

Howdeshell KL, Furr J, Lambright CR, Rider CV, Wilson VS, Gray LE Jr (2007) Cumulative effects of dibutyl phthalate and diethylhexyl phthalate on male rat reproductive tract development: altered fetal steroid hormones and genes. Toxicol Sci 99(1):190–202. https://doi.org/10.1093/toxsci/ktm069

Howdeshell KL, Furr J, Lambright CR, Wilson VS, Ryan BC, Gray LE Jr (2008) Gestational and lactational exposure to ethinyl estradiol, but not bisphenol A, decreases androgen-dependent reproductive organ weights and epididymal sperm abundance in the male long Evans hooded rat. Toxicol Sci 102(2):371–382. https://doi.org/10.1093/toxsci/kfm306

Hsieh MH, Breyer BN, Eisenberg ML, Baskin LS (2008) Associations among hypospadias, cryptorchidism, anogenital distance, and endocrine disruption. Curr Urol Rep 9(2):137–142. https://doi.org/10.1007/s11934-008-0025-0

Hsieh MH, Eisenberg ML, Hittelman AB, Wilson JM, Tasiann GE, Baskin LS (2012) Caucasian male infants and boys with hypospadias exhibit reduced anogenital distance. Hum Reprod 27(6):1577–1580. https://doi.org/10.1093/humrep/deo087

Imperato-McInley J, Binienda Z, Gedney J, Vaughan EDJ (1986) Nipple differentiation in fetal male rats treated with an inhibitor of the enzyme 5 alpha-reductase: definition of a selective role for dihydrotestosterone. Endocrinology 118(1):132–137. https://doi.org/10.1210/endo-118-1-132

Ipulan LA, Suzuki K, Sakamoto Y, Murashima A, Imai Y, Omori A, Nakagata N, Nishinakamura R, Valasek P, Yamada G (2014) Nonmyocytic androgen receptor regulates the sexually dimorphic development of the embryonic bulbocavernous muscle. Endocrinology 155(7):2467–2479. https://doi.org/10.1210/en.2014-1008

Jain VG, Singal AK (2013) Shorter anogenital distance correlates with undescended testis: a detailed genital anthropometric analysis in human newborns. Hum Reprod 28(9):2343–2349. https://doi.org/10.1093/humrep/det286

Jarfelt K, Dalgaa M, Hass U, Borjch J, Jacobsen H, Ladehoff O (2005) Antiandrogenic effects in male rats perinatally exposed to a mixture of di(2-ethylhexyl) phthalate and di(2-ethylhexyl) adipate. Reprod Toxicol 19(4):505–515. https://doi.org/10.1016/j.reprotox.2004.11.005

Jensen TK, Frederiksen H, Kyhl HB, Lassen TH, Swan SH, Bornenh CG, Skakkebak NE, Main KM, Lind DV, Husby S, Andersson AM (2016) Prenatal exposure to phthalates and anogenital distance in male infants from a low-exposed Danish cohort (2010–2012). Environ Health Perspect 124(7):1107–1113. https://doi.org/10.1289/ehp.1509870

Jiang J, Ma L, Yuan L, Wang X, Zhang W (2007) Study on developmental abnormalities in hypospadiac male rats induced by maternal exposure to di-n-butyl phthalate (DBP). Toxicol Appl Pharmacol 232(3):286–293. https://doi.org/10.1016/j.taap.2007.01.018

Jiang JT, Sun WL, Jing YF, Liu SB, Ma Z, Hong Y, Ma L, Qin C, Liu Q, Stratton HJ, Xia SJ (2011) Prenatal exposure to di-n-butyl phthalate induces anorectal malformations in male rat offspring. Toxicology 290(2–3):322–326. https://doi.org/10.1016/j.tox.2011.08.005

Jiang JP, Geng HQ, Lin HW, Yu X-n, Zhang XW, Yang SL, Wang S (2015a) Relationship between anogenital distance and cryptorchidism in human newborns. Zhonghua Nan Ke Xue Baike Zazhi 21(5):432–435

Jiang JT, Xu HL, Zhu YP, Wood K, Li EH, Sun WL, Yuan Q, Xu DL, Liu ZH, Zhao W, Xia SJ (2015b) Reduced Fgf10/Fgfr2 and androgen receptor (AR) in anorectal malformations male rats induced by di-n-butyl phthalate (DBP): a study on the local and systemic toxicology of DBP. Toxicology 338:77–85. https://doi.org/10.1016/j.tox.2015.10.006

Johansson HKL, Svingen T, Fowler PA, Vinggaard AM, Boberg J (2017) Environmental influences on ovarian dysgenesis—developmental windows sensitive to chemical exposures. Nat Rev Endocrinol 13(7):400–414. https://doi.org/10.1038/nrendo.2017.36

Josso N, Cate RL, Picard JY, Vigier B, di Clemente N, Wilson C, Imbeaud S, Pepinsky RB, Guerrier D, Boussin L, Legeai L, Carré-Eusèbe D (1993) Anti-müllerian hormone: the Jost factor. Recent Prog Horm Res 48:1–59

Jost A (1947) Recherches sur la differentiation sexuelle de l’embryon de lapin. Arch Anat Microsc Morphol Exp 36:271–315

Jost A (1953) Problems of fetal endocrinology: the gonadal and hypothalamic hormones. Recent Prog Horm Res 8:379–418
Kita DH, Meyer KB, Venturelli AC, Adams R, Machado DL, Morais RN, Swan SH, Gennings C, Martino-Andrade AJ (2016) Manipulation of pre and postnatal androgen environments and anogenital distance in rats. Toxicology 368–369:152–161. https://doi.org/10.1016/j.tox.2016.08.021

Koopman P, Gubbay J, Vivian N, Goodfellow P, Lovell-Badge R (1991) Male development of chromosomally female mice transgenic for Sry. Nature 351(6322):117–121. https://doi.org/10.1038/35117a0

Kratzchi K (1971) In vitro analysis of the hormonal basis for the sexual dimorphism in the embryonic development of the mouse mammary gland. J Embryol Exp Morphol 25(1):141–153

Kristensen DM, Hass U, Lesnè L, Lottrup G, Jacobsen PR, Desdoits-Lethimonier C, Boberg J, Petersen JH, Toppari J, Jensen TK, Brunak S, Skakkebaek NE, Nelllemann C, Main KM et al (2011) Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. Hum Reprod 26(1):235–244. https://doi.org/10.1093/humrep/deq323

Kristensen DM, Mauzad-Guittot S, Gaudriault P, Lesnè L, Serrano T, Main KM, Jégou B (2016) Analgesic use—prevalence, biomonitoring and endocrine and reproductive effects. Nat Rev Endocrinol 12(7):381–393. https://doi.org/10.1038/ndrendo.2016.55

Kuhl H (2005) Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 8(Suppl 1):3–63. https://doi.org/10.1080/13697130500148875

Laiër P, Metzdorf SB, Borch J, Hagen ML, Hass U, Christiansen S, Axelstad M, Kledal T, Dalgaard M, McKinnell C, Brokkén LJ, Vinggaard AM (2006) Mechanisms of action underlying the antiandrogenic effects of the fungicide prochloraz. Toxicol Appl Pharmacol 213:2. https://doi.org/10.1016/j.taap.2005.10.013

Lassen TH, Frederiksen H, Kylhl HB, Swan SH, Main KM, Andersson AM, Lind DV, Husby S, Wohlfahrt-Veje C, Skakkebaek NE, Jensen TK (2016) Prenatal triclosan exposure and anthropometric measures including anogenital distance in Danish infants. Environ Health Perspect 124(8):1261–1268. https://doi.org/10.1289/ehp.1409637

Lee KY, Shibutani M, Takagi H, Kato N, Takigami S, Uneyama C, Hirose M (2004) Diverse developmental toxicity of di-n-butyl phthalate in both sexes of rat offspring after maternal exposure during the period from late gestation through lactation. Toxicology 203(1–3):221–238. https://doi.org/10.1016/j.tox.2004.06.013

Li M, Qiu L, Zhang Y, Hua Y, Tu S, He Y, Wen S, Wang Q, Wei G (2013) Dose-related effect by maternal exposure to di-(2-ethylhexyl) phthalate plasticizer on inducing hypospadiac male rats. Environ Toxicol Pharmacol 35(1):55–60. https://doi.org/10.1016/j.etap.2012.10.006

Li N, Chen X, Zhou X, Zhang W, Yuan J, Feng J (2015) The mechanism underlying dibutyl phthalate induced shortened anogenital distance and hypospadias in rats. J Pediatr Surg 50(12):2078–2083. https://doi.org/10.1016/j.jpedsurg.2015.08.046

Lin H, Lian QQ, Hu GX, Jin Y, Zhang Y, Hardy DO, Chen GR, Lu ZQ, Sottas CM, Hardy MP, Ge RS (2009) In utero and lactational exposures to diethylyhexyl-phthalate affect two populations of Leydig cells in male Long-Evans rats. Biol Reprod 80(5):882–888. https://doi.org/10.1095/biolreprod.108.072975

Lind DV, Main KM, Kylhl HB, Kristensen DM, Toppari J, Andersen HR, Andersen MS, Skakkebaek NE, Jensen TK (2017) Maternal use of mild analgesics during pregnancy associated with reduced anogenital distance in sons: a cohort study of 1027 mother-child pairs. Hum Reprod 32(1):223–231. https://doi.org/10.1093/humrep/dew285

Liu ZH, Li EH, Xu DL, Sun WL, Hong Y, Zhao W, Xiao SJ, Jiang JT (2016) Genetic research and structural dysplasia assessment of anorectal malformations in neonatal male rats induced by di(n-butyl) phthalate. Environ Toxicol 31(3):261–268. https://doi.org/10.1002/tox.22040

Loeffer IK, Peterson RE (1999) Interactive effects of TCDD and p,p′-DDE on male reproductive tract development in in utero and lactationally exposed rats. Toxicol Appl Pharmacol 154(1):28–39. https://doi.org/10.1006/tap.1998.8572

MacLean HE, Chiu WS, Notini AJ, Azell AM, Davey RA, McManus JF, Ma C, Plant DR, Lynch GS, Zajac JD (2008) Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. FASEB J 22(8):2676–2689. https://doi.org/10.1096/fj.08-105726

MacLeod DJ, Sharpe RM, Welsh M, Fisken M, Scott HM, Hutchinson GR, Drake AJ, van den Driesche S (2010) Androgen action in the masculinization programming window and development of male reproductive organs. Int J Androl 33(2):279–287. https://doi.org/10.1111/j.1365-2609.2009.01005.x

Mammadov E, Uncu M, Dalkan C (2018) High prenatal exposure to bisphenol A reduces anogenital distance in healthy male newborns. J Clin Res Pediatr Endocrinol 10(1):25–29. https://doi.org/10.4274/jcrpe.4817

Mandrup K, Jacobsen PR, Irling LK, Axelstad M, Dreisig K, Hadrup N, Vinggaard AM, Hass U, Boberg J (2013) Effects of perinatal ethinyl estradiol exposure in male and female Wistar rats. Reprod Toxicol 42:180–191. https://doi.org/10.1016/j.reprotox.2013.09.001

Mandrup K, Boberg J, Irling LK, Christiansen S, Hass U (2016) Low-dose effects of bisphenol A on mammary gland development in rats. Andrology 4(4):673–683. https://doi.org/10.1111/and.12193

Marsee K, Woodruff TJ, Axelrad DA, Calafat AM, Swan SH (2006) Estimated daily phthalate exposures in a population of mothers of male infants exhibiting reduced anogenital distance. Environ Health Perspect 114(6):805–809. https://doi.org/10.1289/ehp.8663

Martino-Andrade AJ, Morais RN, Botelho GG, Muller G, Grande SW, Carpentieri GB, Leão GM, Dalsenter PR (2009) Coadministration of active phthalates results in disruption of foetal testicular function in rats. Int J Androl 32(6):704–712. https://doi.org/10.1111/j.1365-2605.2008.00939.x

Masutomi N, Shibutani M, Takagi H, Uneyama C, Takahashi N, Hirose M (2003) Impact of dietary exposure to methoxychlor, genistein, or diisononyl phthalate during the perinatal period on the development of the rat endocrine/reproductive systems in later life. Toxicology 192(2–3):149–170. https://doi.org/10.1016/S0300-483X(03)00269-5

Matsuura I, Saitoh T, Ashina M, Wako Y, Iwata H, Toyota N, Ishizuka Y, Namiki M, Hoshino N, Tsuchitani M (2005a) Evaluation of a two-generation reproduction toxicity study adding endpoints to detect endocrine disrupting activity using vinclozolin. J Toxicol Sci 30(Spec No):163–168 https://doi.org/10.2131/jts.30.S163

Matsuura I, Saitoh T, Tani E, Wako Y, Iwata H, Toyota N, Ishizuka Y, Namiki M, Hoshino N, Tsuchitani M, Ikeda Y (2005b) Evaluation of a two-generation reproduction toxicity study adding endpoints to detect endocrine disrupting activity using lindane. J Toxicol Sci 30(Spec No):135–161 https://doi.org/10.2131/jts.30.S135

McIntyre BS, Barlow NJ, Wallace DG, Maness SC, Gaido KW, Foster PM (2000) Effects of in utero exposure to linuron on androgen-dependent reproductive development in the male Crl:CD(SD) BR rat. Toxicol Appl Pharmacol 167(2):87–99. https://doi.org/10.1006/taap.2000.8998

McIntyre BS, Barlow NJ, Foster PM (2001) Androgen-mediated development in male rat offspring exposed to flutamide in utero: permanence and correlation of early postnatal changes in anogenital distance and nipple retention with malformations in
androgen-dependent tissues. Toxicol Sci 62(2):236–249. https://doi.org/10.1093/toxsci/62.2.236

McIntyre BS, Barlow NJ, Foster PM (2002) Male rats exposed to linuron in utero exhibit permanent changes in anogenital distance, nipple placement, and epididymal malformations that result in subsequent testicular atrophy. Toxicol Sci 65(1):62–70. https://doi.org/10.1093/toxsci/65.1.62

Mckeek RH, Pavkov KL, Trimmer GW, Keller LH, Stump DG (2006) An assessment of the potential developmental and reproductive toxicity of di-isooheptyl phthalate in rodents. Reprod Toxicol 21(3):241–252. https://doi.org/10.1016/j.reprotox.2005.09.002

Melching-Kollmuss S, Fussell KC, Schneider S, Buesen R, Groeters S, Strauss V, van Ravenzwaay B (2017) Comparing effect levels of regulatory studies with endpoints developed in targeted anti-androgenic studies: example prochloraz. Arch Toxicol 91(1):143–162. https://doi.org/10.1007/s00204-016-1678-y

Mendiola J, Stahlhut RW, Jorgensen N, Liu F, Swan SH (2011) Shorter

Miao M, Yuan W, He Y, Zhou Z, Wang J, Gao E, Li G, Li DK (2011)

Mylchreest E, Sar M, Cattley RC, Foster PM (1999) Disruption of

Moore RW, Rudy TA, Lin TM, Ko K, Peterson RE (2001) Abnormalities of sexual development in male rats with in utero and lactational exposure to the antiandrogenic plasticizer di(2-ethylhexyl) phthalate. Environ Health Perspect 109(3):229–237

Mira-Escolano MP, Mendiola J, Minguez-Alarcón L, Meglarejo M, Cutillas-Tolin A, Koca M, López-Espín JJ, Noguera-Velasco JA, Torres-Camtero AM (2014) Longer anogenital distance is associated with higher testosterone levels in women: a cross-sectional study. BJOG 121(11):1359–1364. https://doi.org/10.1111/bjog.12627

Mitchell RT, Mungall W, McKinnell C, Sharpe RM, Cruickshanks L, Milne L, Smith LB (2015) Anogenital distance plasticity in adulthood: implications for its use as a biomarker of fetal androgen action. Endocrinology 156(1):24–31. https://doi.org/10.1210/en.2014-1534

Money J, Mathews D (1982) Prenatal exposure to virilizing progestins: an adult follow-up study of twelve women. Arch Sex Behav 11(1):73–83. https://doi.org/10.1007/BF01541367

Moore RW, Rudy TA, Lin TM, Ko K, Peterson RE (2001) Abnormalities of sexual development in male rats with in utero and lactational exposure to the antiandrogenic plasticizer di(2-ethylhexyl) phthalate. Environ Health Perspect 109(3):229–237

Mylchreest E, Cattley RC, Foster PM (1998) Male reproductive tract malformations in rats following gestational and lactational exposure to di(n-butyl) phthalate: an antiandrogenic mechanism? Toxicol Sci 43(1):47–60. https://doi.org/10.1006/toxs.1998.2436

Mylchreest E, Sar M, Cattley RC, Foster PM (1999) Disruption of androgen-regulated male reproductive development by di(n-butyl) phthalate during late gestation in rats is different from flutamide. Toxicol Appl Pharmacol 156(2):81–95. https://doi.org/10.1006/tapp.1999.8643

Nagao T, Ohta R, Maruho H, Shindo T, Yoshimura S, Ono H (2000) Effect of butyl benzyl phthalate in Sprague-Dawley rats after gavage administration: a two-generation reproductive study. Reprod Toxicol 14(6):513–532. https://doi.org/10.1016/S0890-6238(00)00105-2

Nakamura N, Inselsm AL, White GA, Chang CW, Trbojevich RA, Sephr E, Voris KL, Patton RE, Bryant MS, Harrouk W, McIntyre BS, Foster PM, Hansen DK (2015) Effects of maternal and lactational exposure to 2-hydroxy-4-methoxybenzene on development and reproductive organs in male and female rat offspring. Birth Defects Res B Dev Reprod Toxicol 104(1):35–51. https://doi.org/10.1002/bdbr.21137

Nardelli TC, Albert O, Lalancette C, Culity M, Hales BF, Robaire B (2017) In utero and lactational exposure study in rats to identify

replacements for di(2-ethylhexyl) phthalate. Sci Rep 7(1):3862. https://doi.org/10.1038/s41598-017-03979-0

Nef S, Parada LF (1999) Cryptorchidism in mice mutant for Insl3. Nat Genet 22(3):295–299. https://doi.org/10.1038/10364

Noriega NC, Ostby J, Lambright C, Wilson VS, Gray LE Jr (2005) Late gestational exposure to the fungicide prochloraz delays the onset of parturition and causes reproductive malformations in male but not female rat offspring. Biol Reprod 72(6):1324–1335. https://doi.org/10.1095/biolreprod.104.031385

Notini AJ, Davey RA, McManus JF, Bate KL, Zajac JD (2005) Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model. J Mol Endocrinol 35(3):547–555. https://doi.org/10.1677/jme.1.01884

NTP—National Toxicology Program (2010) Multigenerational reproductive toxicology study of ethinyl estradiol (CAS No. 57-63-6) in Sprague-Dawley rats. Natl Toxicol Program Tech Rep Ser 547:1–312

OECD (2008) Guidance document on mammalian reproductive toxicity testing and assessment. OECD series on testing and assessment no. 43. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2008)16&doclanguage=en. Accessed 1 Jun 2018

OECD (2012) Test no. 443: extended one-generation reproductive toxicity study, OECD guidelines for the testing of chemicals, section 4. OECD Publishing, Paris. https://doi.org/10.1787/9789264185371-en

OECD (2013) Guidance document in support of the test guideline on the extended one generation reproductive toxicity study no. 151. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2013)10&doclanguage=en. Accessed 1 Jun 2018

OECD (2015) Feasibility study for minor enhancements of TG 421/422 with ED relevant endpoints. Environment, health and safety publications, series on testing and assessment (no. 217). Paris http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2015)24&doclanguage=en. Accessed 1 Jun 2018

OECD (2016a) Test no. 421: reproduction/developmental toxicity screening test, OECD guidelines for the testing of chemicals, section 4. OECD Publishing, Paris. https://doi.org/10.1787/978926426380-en

OECD (2016b) Test no. 422: combined repeated dose toxicity study with the reproduction/developmental toxicity screening test, OECD guidelines for the testing of chemicals, section 4. OECD Publishing, Paris. https://doi.org/10.1787/9789264264403-en

OECD (2018) Test no. 414: prenatal development toxicity study, OECD guidelines for the testing of chemicals, section 4. OECD Publishing, Paris. https://doi.org/10.1787/9789264070820-en

Ostby JS, Gray LEJ (2004) Transgenerational (in utero/lactational) exposure to investigate the effects of endocrine disrupting compounds (EDCs) in rats. Curr Protoc Toxicol. https://doi.org/10.1002/0471140856.td1608s19 (Ch 16:unit 16.8)

Ostby J, Kelce WR, Lambright C, Wolf CJ, Mann P, Gray CLJ (1999) The fucoid glycoproteininduces sexual differentiation in the male rat by acting as an androgen-receptor antagonist in vivo and in vitro. Toxicol Ind Health 15(1–2):80–93. https://doi.org/10.1080/07482339901500108

Parks LG, Ostby JS, Lambright CR, Abbott BD, Klinefelter GR, Barlow NJ, Gray LEJ (2000) The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. Toxicol Sci 58(2):339–349. https://doi.org/10.1093/toxsci/58.2.339

Ramezani Tehrani F, Noroozadeh M, Zahediasl S, Piryaee A, Hashemi S, Azizi F (2014) The time of prenatal androgen exposure affects development of polycystic ovary syndrome-like
phenotype in adulthood in female rats. Int J Androlog Metab 12(2):e16502. https://doi.org/10.5812/ijem.16502
Reif DM, Martin MT, Tan SW, Houck KA, Judson RS, Richard AM, Knudsen TB, Dix DJ, Kavlock RJ (2010) Endocrine profiling and prioritization of environmental chemicals using ToxCast data. Environ Health Perspect 118(12):1714–1720. https://doi.org/10.1289/ehp.1002180
Rosenmai AK, Dybdahl M, Pedersen M, Alice van Vught-Lussenburg BM, Wedeye EB, Taxvig C, Vinggaard AM (2014) Are structural analogues to bisphenol a safe alternatives? Toxicol Sci 139(1):35–47. https://doi.org/10.1093/toxsci/kfu030
Ryan BC, Hotchkiss AK, Crofton KM, Gray LE Jr (2010) In utero and lactational exposure to bisphenol A, in contrast to ethinyl estradiol, does not alter sexually dimorphic behavior, puberty, fertility, and anatomy of female LE rats. Toxicol Sci 114(1):133–148. https://doi.org/10.1093/toxsci/kfp266
Saillenfait AM, Sabaté JP, Gallissot F (2008) Diisobutyl phthalate impairs the androgen-dependent reproductive development of the male rat. Reprod Toxicol 26(2):107–115. https://doi.org/10.1016/j.reprotox.2008.07.006
Saillenfait AM, Gallissot F, Sabaté JP (2009a) Differential developmental toxicities of di-n-hexyl phthalate and dicyclohexyl phthalate administered orally to rats. J Appl Toxicol 29(6):510–521. https://doi.org/10.1002/jat.1436
Saillenfait AM, Sabaté JP, Gallissot F (2009b) Effects of in utero exposure to di-n-hexyl phthalate on the reproductive development of the male rat. Reprod Toxicol 28(4):468–476. https://doi.org/10.1016/j.reprotox.2009.06.013
Saillenfait AM, Roudot AC, Gallissot F, Sabaté JP (2011) Prenatal developmental toxicity studies on di-n-heptyl and di-n-octyl phthalates in Sprague-Dawley rats. Reprod Toxicol 32(3):268–276. https://doi.org/10.1016/j.reprotox.2011.08.001
Saillenfait AM, Gallissot F, Sabaté JP, Remy A (2013) Prenatal developmental toxicity studies on diundecyl and ditridecyl phthalates in Sprague-Dawley rats. Reprod Toxicol 37:49–55. https://doi.org/10.1016/j.reprotox.2013.01.004
Saillenfait AM, Sabaté JP, Denis F, Antoine G, Robert A, Roudot AC, Ndiaye D, Eljarrat E (2017) Evaluation of the effects of α-cypermethrin on fetal rat testicular steroidogenesis. Reprod Toxicol 72:106–114. https://doi.org/10.1016/j.reprotox.2017.06.133
Salazar-Martinez E, Romano-Riquer P, Yanez-Marquez E, Longnecker MP, Hernandez-Avila M (2004) Anogenital distance in human male and female newborns: a descriptive, cross-section study. Environ Health 3(1):8. https://doi.org/10.1186/1476-069X-3-8
Satoh K, Nonaka R, Ohyama K, Nagai F (2005) Androgenic and antiandrogenic effects of alkylphenols and parabens assessed using the reporter gene assay with stably transfected CHO-K1 cells (AR-EcoScreen System). J Health Sci 51:557–568. https://doi.org/10.1248/jhs.51.557
Sawaki M, Noda S, Muroi T, Mitoma H, Takakura S, Sakamoto S, Yamasaki K (2003) In utero through lactational exposure to ethinyl estradiol induces cleft phallus and delayed ovarian dysfunction in the offspring. Toxicol Sci 75(2):402–411. https://doi.org/10.1093/toxsci/kfg180
Schneider S, Kaufmann W, Strauss V, van Ravenzwaay B (2011) Vinclozolin: a feasibility and sensitivity study of the ILSI-HESI F1-extended one-generation rat reproduction protocol. Regul Toxicol Pharmacol 59(1):91–100. https://doi.org/10.1016/j.yrtph.2010.09.010
Scott HM, Hutchison GR, Mahood JK, Hallmark N, Welsh M, De Gendt K, Verhoeven H, O’Shaughnessy P, Sharpe RM (2007) Role of androgens in fetal testis development and dysgenesis. Endocrinology 148(5):2027–2036. https://doi.org/10.1210/en.2006-1622
Scott HM, Hutchison GR, Jobling MS, McKinnell C, Drake Sharpe AJ RM (2008) Relationship between androgen action in the “male programming window,” fetal sertoli cell number, and adult testis size in the rat. Endocrinology 149(10):5280–5287. https://doi.org/10.1210/en.2008-0413
Singal AK, Jain VG, Gazali Z, Shekhawat P (2016) Shorter anogenital distance correlates with the severity of hypospadias in pre-puber- tal boys. Hum Reprod 31(7):1406–1410. https://doi.org/10.1093/humrep/dew115
Skakkebaek NE, Rajpert-De Meyts E, Bock Louis GM, Toppari J, Andersson AM, Eisenberg ML, Jensen TK, Jørgensen N, Swan SH, Sapra JK, Zieve S, Priskorn L, Juul A (2016) Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility. Physiol Rev 96(1):55–97. https://doi.org/10.1152/physrev.00017.2015
Stewart MK, Mattiske DM, Pask AJ (2018) In utero exposure to both high and low dose diethylstilbestrol disrupts mouse genital tubule development. Biol Reprod. https://doi.org/10.1093/biolre/ioy142 (in press)
Suzuki Y, Yoshinaga J, Mizumoto Y, Serizawa S, Shiraih H (2012) Foetal exposure to phthalate esters and anogenital distance in male newborns. Int J Androl 35(3):236–244. https://doi.org/10.1111/j.1365-2605.2011.01190.x
Svechnikov K, Izzo G, Landreh L, Weisser J, Süder O (2010) Endocrine disruptors and Leydig cell function. J Biomed Biotechnol 2010:684504. https://doi.org/10.1155/2010/684504
Svechnikov K, Savchuk I, Morvan ML, Antignac JP, Le Bizec B, Süder O (2016) Phthalates exert multiple effects on Leydig cell steroidogenesis. Horm Res Paediatr 86(4):253–263. https://doi.org/10.1158/1947-6501.PS.2015-00440619
Svingen T, Koopman P (2013) Building the mammalian testis: origins, differentiation, and assembly of the component cell populations. Genes Dev 27(22):2409–2426. https://doi.org/10.1101/gad.228080.113
Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, Mao CS, Redmon JB, Ternald CL, Sullivan S, Teague JL, Team SFFR (2005) Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Perspect 113(8):1056–1061. https://doi.org/10.1289/ehp.8100
Takagi H, Shibutani M, Masutomi N, Uneyama C, Takahashi N, Mitsumori K, Hirose M (2004) Lack of maternal dietary exposure effects of bisphenol A and nonylphenol during the critical period for brain sexual differentiation on the reproductive/endoctrine systems in later life. Arch Toxicol 78(2):97–105. https://doi.org/10.1007/s00204-003-0517-0
Taxvig C, Hass U, Axelstad M, Dalgaard M, Boberg J, Andresen HR, Vinggaard AM (2007) Endocrine-disrupting activities in vivo of the fungicides tebuconazole and epoxiconazole. Toxicol Sci 100(2):464–473. https://doi.org/10.1093/toxsci/kfm227
Taxvig C, Vinggaard AM, Hass U, Axelstad M, Metzendorf S, Nelleman C (2008) Endocrine-disrupting properties in vivo of widely used azole fungicides. Int J Androl 31(2):170–177. https://doi.org/10.1111/j.1365-2605.2007.00838.x
Thankamony A, Ong KG, Dunger DB, Acerini CL, Hughes IA (2009) Anogenital distance from birth to 2 years: a population study. Environ Health Perspect 117(11):1786–1790. https://doi.org/10.1289/ehp.0900881
Thankamony A, Lek N, Carroll D, Williams M, Dunger DB, Acerini CL, Ong KG, Hughes IA (2014) Anogenital distance and penile length in infants with hypospadias or cryptorchidism: comparison with normative data. Environ Health Perspect 122(2):207–211. https://doi.org/10.1289/ehp.1307178
Thankamony A, Pasterski V, Ong KG, Acerini CL, Hughes IA (2016) Anogenital distance as a marker of androgen exposure in humans. Andrology 4(4):616–625. https://doi.org/10.1111/andr.12156
Tinwell H, Haseman J, Lefevre PA, Wallis N, Ashby J (2002) Normal sexual development of two strains of rat exposed in utero to low doses of bisphenol A. Toxicol Sci 68:339–348. https://doi.org/10.1093/toxsci/68.2.339

Turner KJ, Barlow NJ, Struve MF, Wallace DG, Gaido KW, Dorman DC, Foster PM (2002) Effects of in utero exposure to the organophosphate insecticide fenitrothion on androgen-dependent reproductive development in the Crl:CD(SD)BR rat. Toxicol Sci 68(1):174–183. https://doi.org/10.1093/toxsci/68.1.174

Tyl RW, Myers CB, Marr MC, Faila PA, Seely JC, Brine DR, Barter RW, Myers CB, Marr MC, Faila PA, Seely JC, Brine DR, Barter RA, Butala JH (2004) Interactive effects of vinclozolin and testosterone propionate on pregnancy and sexual differentiation of the male rat. Environ Toxicol Pharmacol 37(2):705–717. https://doi.org/10.1016/j.etap.2014.01.016

Welsh M, Saunders PT, Sharpe RM (2007) The critical time window for androgen-dependent development of the Wolffian duct in the rat. Endocrinology 148(7):3185–3195. https://doi.org/10.1210/en.2007-0028

Welsh M, Saunders PT, Fiskin M, Scott HM, Hutchison GR, Smith LB, Sharpe RM (2008) Identification in rats of a programming window for reproductive tract masculinization, disruption of which leads to hypospadias and cryptorchidism. J Clin Investig 118(4):1479–1490. https://doi.org/10.1172/JCI42441

Welsh M, MacLeod DJ, Walker M, Smith LB, Sharpe RM (2010) Critical androgen-sensitive periods of rat penis and clitoris development. Int J Androl 33(1):e144–e152. https://doi.org/10.111
1/j.1365-2605.2009.00978.x

Wilkins L, Jones HWI, Holman GH, Stempfel RSI (1958) Masculinization of the female fetus associated with administration of oral and intramuscular progestins during gestation: non-adrenal female pseudohyperphenadism. J Clin Endocrinol Metab 18(6):559–585. https://doi.org/10.1210/jcem-18-6-559

Williams K, McKinnell C, Saunders PT, Walker M, Fisher JS, Turner KJ, Atanassova N, Sharpe M (2001) Neonatal exposure to potent and environmental oestrogens and abnormalities of the male reproductive system in the rat: evidence for importance of the androgen-oestrogen balance and assessment of the relevance to man. Hum Reprod Update 7(3):236–247. https://doi.org/10.1093/humupd/7.3.236

Wolf CJ, Lambright C, Mann P, Price M, Cooper RL, Ostby J, Gray CLJ (1999) Administration of potentially antiandrogenic pesticides (procyemidone, linuron, iprodione, chlozolinate, p,p′-DDE, and ketoconazole) and toxic substances (dibutyl- and diethylhexyl phthalate, PCB 169, and ethane dimethane sulphoxide) during sexual differentiation produces diverse profiles of reproductive malformations in the male rat. Toxicol Ind Health 15(1–2):94–118. https://doi.org/10.1177/074823379901500109

Wolf CJ, Hotchkiss A, Ostby JS, LeBlanc GA, Gray LE Jr (2002) Effects of prenatal testosterone propionate on the sexual development of male and female rats: a dose-response study. Toxicol Sci 65(1):71–86. https://doi.org/10.1093/toxsci/65.1.71

Wolf CJ, LeBlanc GA, Gray LE Jr (2004) Interactive effects of vinclozolin and testosterone propionate on pregnancy and sexual differentiation of the male and female SD rat. Toxicol Sci 78(1):135–143. https://doi.org/10.1093/toxsci/kfh018

Wu Y, Zhong G, Chen S, Zheng C, Liao D, Xie M (2017) Polycystic ovary syndrome is associated with anogenital distance, a marker of prenatal androgen exposure. Hum Reprod 32(4):937–943. https://doi.org/10.1093/humrep/dex042

Zhang L, Dong L, Ding S, Qiao P, Wang C, Zhang M, Zhang L, Du Q, Li Y, Tang N, Chang B (2014) Effects of n-butylparaben on steroidogenesis and spermatogenesis through changed E2 levels in male rat offspring. Environ Toxicol Pharmacol 37(2):705–717. https://doi.org/10.1016/j.etap.2014.01.016